Saravanan, Ponnusamy http://orcid.org/0000-0002-9566-2626
Bell, Heather
Braae, Uffe Christian http://orcid.org/0000-0002-2743-4584
Collins, Edward
Deinega, Alisa http://orcid.org/0000-0001-6314-0471
Dhatariya, Ketan http://orcid.org/0000-0003-3619-9579
Machell, Alena http://orcid.org/0009-0007-1962-6061
Trent, Antonia
Strzelecka, Anna
Article History
Received: 17 July 2024
Accepted: 14 August 2024
First Online: 24 September 2024
Declarations
:
: The authors disclose the following competing interests: Ponnusamy Saravanan: honoraria or travel support from Novo Nordisk and Abbott, UK; an unrestricted educational grant from Novo Nordisk A/S to set up an international Doctoral Training Partnership. Heather Bell: honoraria, travel support or fees for advisory boards from Abbott, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Menarini, Novo Nordisk, PCDS, Roche. Uffe Christian Braae: employee and shareholder of Novo Nordisk A/S. Edward Collins: employee and shareholder of Novo Nordisk A/S. Alisa Deinega: employee of Novo Nordisk A/S. Ketan Dhatariya: honoraria, travel support or fees for advisory boards from AstraZeneca, Novo Nordisk, Boehringer-Ingelheim, Eli Lilly, Abbott Diabetes, Menarini, Sanofi. Alena Machell: honoraria, travel support or fees for advisory boards from Novo Nordisk, Abbott. Antonia Trent: employee of Novo Nordisk A/S. Anna Strzelecka: honoraria from Astra Zeneca, Boehringer Ingelheim, Janssen, Lilly, MSD, Novo Nordisk, NAPP.
: The study protocol was approved centrally by the UK National Health Services Health Research Authority (NHS HRA) and the Medicines and Healthcare products Regulatory Agency (MHRA) after review by the London-Chelsea Research Ethics Committee (for all sites). The study was conducted following good pharmacoepidemiology practices (GPP) []) and good pharmacovigilance practices (GVP) [] in accordance with the Declaration of Helsinki []. All participants signed an informed consent.